IGXT (Mkap $34 M) 2 US-Zulassungsanträge im 4Q + weiteres Produkt wartet auf FDA Zulassung (Seite 111)
eröffnet am 27.07.16 17:27:05 von
neuester Beitrag 21.03.24 14:04:18 von
neuester Beitrag 21.03.24 14:04:18 von
Beiträge: 1.197
ID: 1.235.830
ID: 1.235.830
Aufrufe heute: 2
Gesamt: 195.664
Gesamt: 195.664
Aktive User: 0
ISIN: US45822R1014 · WKN: A0RP0X
0,1770
EUR
+6,63 %
+0,0110 EUR
Letzter Kurs 12:33:44 Lang & Schwarz
Neuigkeiten
08.04.24 · globenewswire  |
05.04.24 · globenewswire |
21.03.24 · globenewswire |
14.03.24 · globenewswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2000 | +471,16 | |
| 0,8700 | +134,44 | |
| 0,5700 | +55,23 | |
| 5,4500 | +41,56 | |
| 119,40 | +29,92 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6500 | -10,96 | |
| 2,8800 | -12,73 | |
| 0,8744 | -13,43 | |
| 4,1900 | -14,49 | |
| 1,4500 | -20,98 |
Beitrag zu dieser Diskussion schreiben
Feedback
Die News scheint noch nicht weit genug verbreitet zu sein...
Einige Shortis haben aber bestimmt schon Eisfüsse
Einige Shortis haben aber bestimmt schon Eisfüsse
Antwort auf Beitrag Nr.: 53.111.232 von Maggi110 am 22.08.16 15:11:11dann stehen ganz sicher 2 Stellen vorm Komma!!!! Könnte hier ein richtig lohnendes Invest werden.
Antwort auf Beitrag Nr.: 53.111.232 von Maggi110 am 22.08.16 15:11:11Mal schauen was heute der Tag in den USA so bringt, Preis+Volumen.... bin gespannt
Antwort auf Beitrag Nr.: 53.111.088 von Biohero am 22.08.16 14:43:40Sollte die Studie im nä Jahr gute Ergebnisse liefern dann 
Evtl haben wir hier durch Biohero einen guten Fang gemacht!
Evtl haben wir hier durch Biohero einen guten Fang gemacht!
Antwort auf Beitrag Nr.: 53.110.998 von Popeye82 am 22.08.16 14:34:09GuteNews kommen genau zur richtigen Zeit könnte ein schöner Tag werden für IGXT und deren Aktionäre .
IntelGenx Announces Successful Clinical Study for Montelukast for the Treatment of Degenerative Diseases of the Brain.............August 22, 2016
http://www.intelgenx.com/investors/press-releases/press-rele…
"We are very pleased by the results of the study which confirmed that our Montelukast VersaFilm™ significantly improves the bioavailability of the drug when given as an oral film product. The study demonstrates that the VersaFilm™ technology is an effective delivery system for CNS applications," said Dr. Horst G. Zerbe, President and CEO of IntelGenx. "Montelukast is an important drug repurposing opportunity that the company has in its product pipeline which could potentially become a multi-billion-dollar product in the large and underserved market for degenerative diseases of the brain."
IntelGenx Announces Successful Clinical Study for Montelukast for the Treatment of Degenerative Diseases of the Brain.............August 22, 2016
http://www.intelgenx.com/investors/press-releases/press-rele…
"We are very pleased by the results of the study which confirmed that our Montelukast VersaFilm™ significantly improves the bioavailability of the drug when given as an oral film product. The study demonstrates that the VersaFilm™ technology is an effective delivery system for CNS applications," said Dr. Horst G. Zerbe, President and CEO of IntelGenx. "Montelukast is an important drug repurposing opportunity that the company has in its product pipeline which could potentially become a multi-billion-dollar product in the large and underserved market for degenerative diseases of the brain."
Trading Spotlight
Antwort auf Beitrag Nr.: 53.107.743 von URANI am 22.08.16 08:28:13
IntelGenx Announces Successful Clinical Study for Montelukast for the Treatment of Degenerative Diseases of the Brain
SAINT-LAURENT, CANADA -- (Marketwired) -- 08/22/16 -- IntelGenx Corp., (TSX VENTURE:IGX)(OTCQX:IGXT), today announced the successful completion of a pilot clinical study for Montelukast VersaFilm(TM) that demonstrated a significantly improved pharmacokinetic profile against the reference product. Montelukast is a unique drug repurposing opportunity for the treatment of degenerative diseases of the brain, such as mild cognitive impairment and Alzheimer's disease, the most prominent form of dementia.
The study data confirmed that buccal absorption of the drug from the Montelukast film product resulted in a significally improved bioavailability of the drug compared to the commercial tablet. The study was designed as a single-dose, randomized, two-way cross-over pilot study in 8 healthy subjects. AUC0-inf was 3863 +/- 1343 ng/ml(i)h-1 for the IntelGenx product vs. 2697 +/- 1003 ng/ml(i)h-1 for the reference product Singulair(R) tablets, representing a 52% increase in bioavailability of the drug after administration of the IntelGenx film product. In addition, the study data confirmed that Montelukast crosses the blood/brain barrier when administered using IntelGenx' Versafilm(TM) delivery technology.
The Company has begun preparation for a phase II-a proof-of-concept (POC) study. Patient enrolment for this study is expected to commence in Q1/2017. The Company expects the results from the study to be available in Q4/2017. Based on the outcome of this first efficacy trial in humans, IntelGenx will be actively seeking a partnership or alliance opportunity to further advance developmental work and commercialization of this product.
"We are very pleased by the results of the study which confirmed that our Montelukast VersaFilm(TM) significantly improves the bioavailability of the drug when given as an oral film product. The study demonstrates that the VersaFilm(TM) technology is an effective delivery system for CNS applications," said Dr. Horst G. Zerbe, President and CEO of IntelGenx. "Montelukast is an important drug repurposing opportunity that the company has in its product pipeline which could potentially become a multi-billion-dollar product in the large and underserved market for degenerative diseases of the brain."
IntelGenx is collaborating with Dr. Ludwig Aigner, a neuroscientist who is a member of IntelGenx Scientific Advisory Board and head of the Institute of Molecular Regenerative Medicine at the Paracelsus Medical University in Salzburg, Austria. Dr. Aigner has made major contributions in the field of brain and spinal cord regeneration over the last 25 years. He was the first to develop tools to visualize neurogenesis in living animals and identified signaling mechanisms that are crucially involved in limiting brain regeneration. One of these mechanisms, leukotriene signaling, is related to asthma. In consequence, Dr. Aigner and his team recently demonstrated that the anti-asthmatic drug montelukast structurally and functionally rejuvenates the aged brain. His main aim is to develop molecular and cellular therapies for patients with neurodegenerative diseases and for the aged population. A video interview with Dr. Aigner discussing montelukast is available at:
http://www.intelgenx.com/product/Montelukast/default.aspx
IntelGenx Announces Successful Clinical Study for Montelukast for the Treatment of Degenerative Diseases of the Brain
SAINT-LAURENT, CANADA -- (Marketwired) -- 08/22/16 -- IntelGenx Corp., (TSX VENTURE:IGX)(OTCQX:IGXT), today announced the successful completion of a pilot clinical study for Montelukast VersaFilm(TM) that demonstrated a significantly improved pharmacokinetic profile against the reference product. Montelukast is a unique drug repurposing opportunity for the treatment of degenerative diseases of the brain, such as mild cognitive impairment and Alzheimer's disease, the most prominent form of dementia.
The study data confirmed that buccal absorption of the drug from the Montelukast film product resulted in a significally improved bioavailability of the drug compared to the commercial tablet. The study was designed as a single-dose, randomized, two-way cross-over pilot study in 8 healthy subjects. AUC0-inf was 3863 +/- 1343 ng/ml(i)h-1 for the IntelGenx product vs. 2697 +/- 1003 ng/ml(i)h-1 for the reference product Singulair(R) tablets, representing a 52% increase in bioavailability of the drug after administration of the IntelGenx film product. In addition, the study data confirmed that Montelukast crosses the blood/brain barrier when administered using IntelGenx' Versafilm(TM) delivery technology.
The Company has begun preparation for a phase II-a proof-of-concept (POC) study. Patient enrolment for this study is expected to commence in Q1/2017. The Company expects the results from the study to be available in Q4/2017. Based on the outcome of this first efficacy trial in humans, IntelGenx will be actively seeking a partnership or alliance opportunity to further advance developmental work and commercialization of this product.
"We are very pleased by the results of the study which confirmed that our Montelukast VersaFilm(TM) significantly improves the bioavailability of the drug when given as an oral film product. The study demonstrates that the VersaFilm(TM) technology is an effective delivery system for CNS applications," said Dr. Horst G. Zerbe, President and CEO of IntelGenx. "Montelukast is an important drug repurposing opportunity that the company has in its product pipeline which could potentially become a multi-billion-dollar product in the large and underserved market for degenerative diseases of the brain."
IntelGenx is collaborating with Dr. Ludwig Aigner, a neuroscientist who is a member of IntelGenx Scientific Advisory Board and head of the Institute of Molecular Regenerative Medicine at the Paracelsus Medical University in Salzburg, Austria. Dr. Aigner has made major contributions in the field of brain and spinal cord regeneration over the last 25 years. He was the first to develop tools to visualize neurogenesis in living animals and identified signaling mechanisms that are crucially involved in limiting brain regeneration. One of these mechanisms, leukotriene signaling, is related to asthma. In consequence, Dr. Aigner and his team recently demonstrated that the anti-asthmatic drug montelukast structurally and functionally rejuvenates the aged brain. His main aim is to develop molecular and cellular therapies for patients with neurodegenerative diseases and for the aged population. A video interview with Dr. Aigner discussing montelukast is available at:
http://www.intelgenx.com/product/Montelukast/default.aspx
Wäre nicht schlecht, wenn jetzt eine News nachgeschoben werden würde :-)
Antwort auf Beitrag Nr.: 53.090.271 von Maggi110 am 18.08.16 21:41:078% lag das Teil an dem Tag im Plus und bist immer noch am winseln, das nenn ich mal Luxus 
Antwort auf Beitrag Nr.: 53.098.110 von Biohero am 19.08.16 20:23:14
Schnöer Entspurt und wieder über eine Million Aktien gehandelt
Nächste Woche wird weiter gegen Norden gehen
Zitat von Biohero: Ist schwer hier eine Prognose abzugeben aber wenn volumen so stabil bleibt könnten wir nächste Woche die $1 Marke nach langer Zeit wieder knacken erst recht wenn gute News veröffentlicht werden .
Schnöer Entspurt und wieder über eine Million Aktien gehandelt
Nächste Woche wird weiter gegen Norden gehen
Durchsuchen
